NUVB

Nuvation Bio Inc. (NUVB) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth Runway

Revenue base remains small, leaving room for multi-year scaling if adoption continues.

Gross margin is very high at 93.9%, which supports operating leverage over time.

Profitability

TTM margins remain deeply negative, with EBIT margin at -76.0% and net margin at -88.2%.

Return metrics are still poor, including ROIC at -20.7% and ROE at -49.7%.

Financial Strength

Liquidity is very strong, with a current ratio of 8.37 and quick ratio of 8.14.

Balance sheet leverage remains manageable, with debt-to-equity at 0.99 and net debt to EBITDA near flat at 0.05.

Cash Generation

Operating cash flow and free cash flow remain negative, with FCF yield at -3.8% and OCF yield at -9.5%.

Cash conversion remains weak, reflecting a negative operating cash flow ratio and persistent losses.

Valuation

The stock still trades at a rich sales multiple, with EV/Sales at 12.7x.

Valuation is hard to anchor on earnings or cash flow because both remain negative.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nuvation Bio Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →